Skip to content

Efficacy of a topical formulation of Myrtus communis L. on chronic anal fissure

Efficacy of a topical formulation of Myrtus communis L. for patients with chronic anal fissure

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20121031011341N10
Enrollment
60
Registered
2018-04-16
Start date
2018-04-04
Completion date
Unknown
Last updated
2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic anal Fissure. Chronic anal Fissure

Interventions

Intervention 1: Topical formulation of Myrtus communis L, three times a day on anus. Intervention 2: Diltiazem, three times a day on anus.

Sponsors

Fasa University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:the age over 18 years to maximum 70 years;The presence of symptoms of chronic anal fissure (including: bleeding, pain, or both,) for more than 6 weeks;the presence of anal fissure in physical exam;the appearance of horizontal fibers of internal anal sphincter and or sentinel anal tag or hypertrophic papilla;;written informed consent for inclusion.

Exclusion criteria

Exclusion criteria: Exclusion criteria:sensitivity and allergy to Myrtus communis L. or Diltiazem or Acetaminophen ;anal or rectal surgeries during 12 weeks ago;inflammatory bowel disease;others anal disease including abscess,fistula,moderate or severe eczema around anus or mass(pile);Immunodeficiency diseases;A history of diseases that require continued consumption of analgesics;any cardio-vascular or cerebro-vascular disease;consumption of calcium channel blochers drugs in general or current use of them in threatment of fissure;history of radiotherapy to pelvic region;anal fibrosis or fixed stenosis;history of important renal ,liver,neurologic,hematologic and psychiatry diseases;history of stool incontinency;history of chronic constipation or constipation during 4 weeks ago( 2 episodes defication or less weekly with straining or dense stool passing);pregnancy and lactation;alcohol and opium addiction;inability to cooperate in completing forms(mood disorders or language problems)

Design outcomes

Primary

MeasureTime frame
Discomfort during defication. Timepoint: At the beginning of intervention and every week by phone call. Method of measurement: Visual Analogue Scale.;Anal pain after defication. Timepoint: At the beginning of intervention and every week by phone call. Method of measurement: Visual Analogue Scale.;Anal bleeding. Timepoint: At the beginning of intervention and every week by phone call. Method of measurement: Visual Analogue Scale.

Secondary

MeasureTime frame
Patient's Global Impression of Improvement (PGI-I). Timepoint: At the beginning of intervention and every two weeks in person. Method of measurement: Visual Analogue Scale.;Reepithelialization. Timepoint: At the beginning of intervention and every two weeks in person. Method of measurement: Physical exam.;Comparison of possible complications of topical formulation of Myrtus communis L.with Diltiazem. Timepoint: Every week by phone call. Method of measurement: Question by check list.;Comparison of topical formulation of Myrtus communis L.with Diltiazem at amount of acetaminophen consumption. Timepoint: Every week by phone call. Method of measurement: Based on counting pills.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Abdolali Pakdaman

Fasa University of Medical Sciences

mehrdadpak48@gmail.com+98 71 5335 0996

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026